Latest news
Future Vision II (FVN): Karpus Management discloses 12.66% ownership of common shares - Stock TitanStock Titan · Fri, 07 Aug 2026 20:04:21 GMTNASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:01 PM - BitgetBitget · Fri, 07 Aug 2026 05:40:06 GMTPROTAGONIST THERAPEUTICS, INC. : LEERINK PARTNERS RAISES TARGET PRICE TO $150.00 FROM $110.00 - BitgetBitget · Thu, 06 Aug 2026 16:16:59 GMTINSULET CORPORATION : BENCHMARK CUTS TARGET PRICE TO $185 FROM $250 - BitgetBitget · Thu, 06 Aug 2026 16:00:13 GMTNASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:34 AM - BitgetBitget · Thu, 06 Aug 2026 07:34:02 GMTNASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:18 PM - BitgetBitget · Wed, 29 Jul 2026 07:00:00 GMTFuture Vision II Acquisition Corp (FVN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKeyTradingKey · Mon, 27 Jul 2026 20:52:08 GMTFVN|Future Vision II Acquisition Corp|Price:11.000|Chg%:+1.690 - TradingKeyTradingKey · Sun, 26 Jul 2026 07:37:21 GMT